Expectations trend
FY2028 · fiscal year ending 2028-05-31 · fmp
Neogen (NEOG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$11.68-6.26%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.38 → 0.44 EPS · FY ending May 31, 2028 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NEOG yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Sustain positive earnings per share growth | A supporting condition in Neogen's published investment case. The stated target is EPS >= $0.30 in FY26. | Improving | EPS falls below $0.25 in FY26 | Diluted EPS: $-0.05 per share FY2027-Q1; GAAP. Published target: EPS >= $0.30 in FY26. Annual target cannot be compared with a quarterly or TTM observation. Oct 7, 2026-0.05 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-05-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is an execution-led recovery story, not yet a durable compounder, because the evidence still describes the business as loss-making. The long-term thesis is intact, with momentum improving, but elevated risk and medium confidence make the setup uncertain.
NEOG is valued at a 1.59 premium to peers, so its valuation looks expensive relative to them. The expectations gap is 0.55, and the evidence flags re-rating as the driver, but does not detail exactly what growth the market assumes.
Near term, recent results are strong: NEOG reported earnings beats in July and October, momentum rose, and FY27 revenue guidance was raised. Management says the Petrifilm transition remains on track, while the Genomics sale has regulatory reviews ongoing; the company is still loss-making, and guidance cuts or weaker employment could pressure the business outlook.
Over the next year, the thesis depends on sustaining revenue momentum and completing the Petrifilm transition on schedule, while progressing the Genomics sale. A guidance cut or further labor-market weakness would be negative; continued earnings strength among healthcare peers would support the sector backdrop.
For the 1-3 year view, NEOG has improving execution and an intact thesis, but losses, elevated risk, and an expensive peer valuation leave little room for setbacks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It plans to finish Petrifilm manufacturing transition by November 2027. |
| Intact |
| Transition not complete by November FY27 |
Transition nears start vs Nov FY27 target FY27 guidance issued with Petrifilm transfer nearing start; Q1 FY27 earnings beat expectations. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 4 supplied quarters. Management reported: “Business and Operational Highlights • The Company remains on track to manufacture saleable Petrifilm product and begin its planned multi-quarter manufacturing transition of Petrifilm to its Lansing manufacturing site beginning in November 2026.” “Business and Operational Highlights • The Company is on track to manufacture sellable Petrifilm ® product and begin its planned multi-quarter manufacturing transition of Petrifilm ® to its Lansing manufacturing site beginning in November 2026.” Delivery assessment Nov 5, 2026 |
Achieve fiscal 2026 revenue of at least $857 million | Neogen aims for $857-$860 million revenue in fiscal 2026. | Intact | Revenue falls below $845 million in FY26 | Revenue: $222.8M FY2027-Q1; GAAP. Published target: >= $857 million. Annual target cannot be compared with a quarterly or TTM observation. Oct 7, 2026222,800,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.35 → $0.44 · observed estimates
$0.84B → $0.85B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-25 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-26 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-27 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-28 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-29 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-30 | $0.35 | $842,956,333 | 2 / 3 |
| 2026-07-31 | $0.39 | $883,323,000 | 1 / 3 |
| 2026-08-01 | $0.39 | $877,600,000 | 1 / 3 |
| 2026-08-02 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-08-03 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-04 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-05 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-08-06 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-07 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-08 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-08-09 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-10 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-08-12 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-08-13 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-14 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-15 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-16 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-17 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-18 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-19 | $0.41 | $851,300,000 | 2 / 4 |
| 2026-08-20 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-21 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-22 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-23 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-24 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-25 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-26 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-27 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-28 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-29 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-30 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-08-31 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-01 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-02 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-03 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-04 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-05 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-06 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-07 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-08 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-09 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-10 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-11 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-12 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-13 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-14 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-15 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-16 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-17 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-18 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-19 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-20 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-21 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-22 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-23 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-24 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-25 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-26 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-27 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-28 | $0.41 | $851,300,000 | 3 / 4 |
| 2026-09-29 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-09-30 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-01 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-02 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-03 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-04 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-05 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-06 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-07 | $0.38 | $865,650,000 | 3 / 4 |
| 2026-10-08 | $0.42 | $871,911,250 | 3 / 4 |
| 2026-10-09 | $0.42 | $871,911,250 | 3 / 4 |
| 2026-10-10 | $0.42 | $871,911,250 | 3 / 4 |
| 2026-10-11 | $0.42 | $871,911,250 | 3 / 4 |
| 2026-10-12 | $0.42 | $873,286,250 | 3 / 4 |
| 2026-10-13 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-14 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-15 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-16 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-17 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-18 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-19 | $0.40 | $874,511,250 | 3 / 4 |
| 2026-10-20 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-21 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-22 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-23 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-24 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-25 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-26 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-27 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-28 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-29 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-30 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-10-31 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-11-01 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-11-02 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-11-03 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-11-04 | $0.44 | $854,236,250 | 2 / 3 |
| 2026-11-05 | $0.44 | $854,236,250 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.